Skip to main content
Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc. — Investor Relations & Filings

Ticker · PRAX ISIN · US74006W2070 US Manufacturing
Open in API
Filings indexed 458 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US PRAX

About Praxis Precision Medicines, Inc.

https://praxismedicines.com/

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders. The company's methodology involves translating insights from genetic epilepsies into treatments for conditions characterized by neuronal excitation-inhibition imbalance. Praxis employs a genetics-focused approach, utilizing translational tools and patient-guided development strategies to advance its portfolio. The developmental pipeline includes several clinical-stage assets and numerous early-stage programs designed to address complex brain disorders.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 85% confidence The document is a Current Report on Form 8-K filed with the U.S. SEC. It reports ‘Other Events’ concerning clinical trial results and program updates under Item 8.01. It is not an earnings release, management change, or financial report itself but rather a regulatory filing disclosing material events. Under the taxonomy, standalone SEC Form 8-K filings with miscellaneous event disclosures fall under Regulatory Filings (RNS).
2026-06-01 English
8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
Regulatory Filings
2026-05-13 English
10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes an announcement regarding the FDA's acceptance of a New Drug Application and a target action date, which is an event update rather than a financial report or detailed analysis. The document length is 2929 characters, which is relatively short and primarily serves as an announcement of a significant event. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-14 English
10-K - PRAXIS PRECISION MEDICINES, INC. (0001689548) (Filer)
Annual Report FY 2025
2026-02-19 English
8-K - PRAXIS PRECISION MEDICINES, INC. (0001689548) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 19, 2026, by Praxis Precision Medicines, Inc. It announces the company's financial results for the quarter and full year ended December 31, 2025, and includes a press release as an exhibit. The text explicitly states that the press release contains the financial results announcement. The document is relatively short (3630 characters) and primarily serves as a notification of the earnings release rather than the full detailed financial report itself. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2026-02-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.